Biotech company Illumina (NASDAQ:ILMN) sank in pre-market trading on Friday after the gene sequencing firm’s outlook left investors disappointed. The company now expects its FY23 revenues to decline by 2% to 3% year-over-year versus its prior expectation of revenues remaining flat. Core Illumina revenues are likely to fall by 3% to 4% year-over-year, while revenues for its GRAIL business segment are projected to be in the low end of the firm’s $90 million to $110 million range.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
In addition, its adjusted loss in FY23 is anticipated to be between $0.60 to $0.70 per share.
Jacob Thaysen, Illumina’s CEO, commented on the lowered outlook, stating that he remains confident in the firm’s ability to achieve long-term success. In addition, management will remain focused on boosting consumables demand.
In the third quarter, the company’s revenues remained flat year-over-year at $1.12 billion as compared to analysts’ estimates of $1.13 billion. Its adjusted earnings came in at $0.33 per share, surpassing analysts’ consensus estimates of $0.13 per share.
Is ILMN a Good Stock to Buy?
Analysts remain cautiously optimistic about ILMN stock, with a Moderate Buy consensus rating based on seven Buys, three Holds and three Sells. The average ILMN price target of $189.92 implies an upside potential of 77.5% at current levels.
